Atara Biotherapeutics Inc (ATRA)
0.6036
-0.03
(-4.15%)
USD |
NASDAQ |
May 07, 16:00
0.6026
0.00 (0.00%)
After-Hours: 05:31
Atara Biotherapeutics Cash from Financing (Quarterly): 1.512M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.512M |
| September 30, 2023 | -0.208M |
| June 30, 2023 | 0.471M |
| March 31, 2023 | 0.235M |
| December 31, 2022 | 32.29M |
| September 30, 2022 | -0.214M |
| June 30, 2022 | 1.157M |
| March 31, 2022 | 19.85M |
| December 31, 2021 | 51.47M |
| September 30, 2021 | 47.14M |
| June 30, 2021 | 2.447M |
| March 31, 2021 | 2.892M |
| December 31, 2020 | 178.80M |
| September 30, 2020 | 33.51M |
| June 30, 2020 | 191.32M |
| March 31, 2020 | 23.96M |
| December 31, 2019 | 37.45M |
| September 30, 2019 | 145.94M |
| June 30, 2019 | 7.327M |
| March 31, 2019 | -1.926M |
| December 31, 2018 | 6.021M |
| September 30, 2018 | -0.515M |
| Date | Value |
|---|---|
| June 30, 2018 | 56.02M |
| March 31, 2018 | 296.01M |
| December 31, 2017 | 0.698M |
| September 30, 2017 | 9.87M |
| June 30, 2017 | 9.806M |
| March 31, 2017 | -0.326M |
| December 31, 2016 | 0.331M |
| September 30, 2016 | 0.199M |
| June 30, 2016 | -0.006M |
| March 31, 2016 | -0.018M |
| December 31, 2015 | 0.185M |
| September 30, 2015 | 194.06M |
| June 30, 2015 | -4.51M |
| March 31, 2015 | 69.49M |
| December 31, 2014 | 58.09M |
| September 30, 2014 | -0.548M |
| June 30, 2014 | -0.736M |
| March 31, 2014 | 13.47M |
| December 31, 2013 | 38.41M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 1.492M |
| March 31, 2013 | 13.47M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.214M
Minimum
Sep 2022
191.32M
Maximum
Jun 2020
40.91M
Average
19.85M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | -0.026M |
| Palatin Technologies Inc | 4.974M |
| iBio Inc | 4.005M |
| Theriva Biologics Inc | -1.457M |
| Oragenics Inc | -0.1806M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -50.41M |
| Cash from Investing (Quarterly) | 9.944M |
| Free Cash Flow | -194.20M |
| Free Cash Flow Per Share (Quarterly) | -0.4664 |
| Free Cash Flow to Equity (Quarterly) | -50.45M |
| Free Cash Flow to Firm (Quarterly) | -49.98M |
| Free Cash Flow Yield | -303.8% |